Mylan and Pfizer announced Sanjeev Narula, Chief financial officer (CFO) of Upjohn, as incoming CFO of Viatris. Both the companies have also announced the remaining appointees to the inaugural 13-member Board of Directors.
Viatris is a new company that will result from the combination of Mylan and Upjohn. The company is expected to enter the market in mid-2020, subjected to regulatory approvals. Pfizer has earlier appointed Ian Read, and Jim Kilts as the board of directors for Viatris; also appointed Pfizer board member W. Don Cornwell as one of the directors. Mylan has appointed JoEllen Lyons Dillon, Neil Dimick, Melina Higgins, Harry A. Korman, Rajiv Malik, Richard A. Mark, Mark W. Parrish, and Pauline van der Meer Mohr to serve as Viatris Board of Directors. Viatris Executive Chairman Robert J. Coury and Viatris CEO Michael Goettler were also included as the board of directors for Viatris.
Dr. Albert Bourla, Pfizer Chairman and CEO, said: “This talented Board of Directors is ideally positioned to serve Viatris on behalf of its shareholders. Besides, I’m thrilled that Don Cornwell will be joining Ian Read and Jim Kilts on the Board of Viatris.”
On the appointment of Sanjeev as CFO, Dr. Albert Bourla said: “Sanjeev’s global experience, proven leadership, and deep industry knowledge will serve Viatris employees, customers and shareholders, well. I am very confident that his commitment to excellence will be instrumental as the new company charts its path as a champion for global health.”
Mylan Chairman, and incoming Viatris Executive Chairman, Robert J. Coury said: “I am pleased to welcome Mr. Cornwell to the Viatris board. Having spent time getting to know him, I am confident that his diverse experience and leadership will bring an important perspective to the Viatris Board.”